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Abstract
Background: Epidemiological studies suggested the chemopreventive role of higher calcium
intake in colorectal carcinogenesis. We examined genetic polymorphisms that might influence
calcium metabolism: lactase (LCT) gene 13910 C/T polymorphism causing lactose intolerance and
calcium-sensing receptor (CaSR) gene A986S polymorphism as a responsible factor for the altered
cellular calcium sensation.
Methods: 538 Hungarian subjects were studied: 278 patients with colorectal cancer and 260
healthy controls. Median follow-up was 17 months. After genotyping, the relationship between LCT
13910 C/T and CaSR A986S polymorphisms as well as tumor incidence/progression was
investigated.
Results: in patient with colorectal cancer, a significantly higher LCT CC frequency was associated
with increased distant disease recurrence (OR = 4.04; 95% CI = 1.71–9.58; p = 0.006). The disease
free survival calculated from distant recurrence was reduced for those with LCT CC genotype (log
rank test p = 0.008). In case of CaSR A986S polymorphism, the homozygous SS genotype was more
frequent in patients than in controls (OR = 4.01; 95% CI = 1.33–12.07; p = 0.014). The number of
LCT C and CaSR S risk alleles were correlated with tumor incidence (p = 0.035). The CCSS
genotype combination was found only in patients with CRC (p = 0.033).
Conclusion: LCT 13910 C/T and CaSR A986S polymorphisms may have an impact on the
progression and/or incidence of CRC.
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Colorectal cancer (CRC) was shown as the second most
common of the leading causes of death from cancer in
developed countries [1]. Even though colorectal tumor-
genesis is a complex process, epidemiological and experi-
mental data indicate that calcium has a chemopreventive
role in the development of CRC [2]. In lactose intolerance
(LI), both calcium intake and absorption are decreased
[3,4]. In Finnish families, a linkage disequilibrium (LD)
analysis showed a 47-kb interval locus in 2q21 chromo-
some region contributing to the trait of LI. Sequence anal-
ysis of this region and subsequent association analyses
revealed an association between the clinically and bio-
chemically verified LI and a C/T polymorphism in the
position of 13910 of the lactase gene (LCT). The cis-acting
element properties of this polymorphism, influencing the
LCT gene promoter activity, may – at least partly – explain
the reduced enzymatic activity of the encoded protein,
called lactase or lactose-phlorizin hydrolase (LPH) [5].
Diminished LPH activity will result in LI leading to lactose
malabsorption that is accompanied with decreased cal-
cium intake [3,4].
Rasinpera et al. [6] have demonstrated that the CC geno-
type of the LCT gene is significantly associated with
increased risk of colorectal cancer in the Finnish popula-
tion but not in the British or Spanish subjects. Hungarians
originate from the Finn-Ugor tribal family and the inci-
dence of LI is in the same range in both populations (20–
35%). Therefore, the potential association between the
LCT 13910 C/T polymorphism and CRC in the Hungarian
population could be postulated.
Calcium-sensing receptor (CaSR) is one of the key factors
on cell surfaces, which by sensing the extracellular cal-
cium concentration in the target organs responds to the
changes in calcium level, thus, mediates signals towards
the inside of the cell. This process is an important step in
calcium homeostasis. A connection has been found
between the CaSR A986S (G/T) polymorphism and serum
calcium concentrations within the normal range in
healthy subjects [7]. In addition, CaSR has a significant
role in cell proliferation [8-10]. Reduced or loss of CaSR
expression was observed in undifferentiated primary
colon cancer cells compared with normal colonic epithe-
lial cells [11]. Disruption of this ligand/receptor system
may contribute to an abnormal differentiation and malig-
nant progression. On the other hand, higher extracellular
calcium through the intact CaSR might protect from CRC
regulating the differentiation and proliferation of colonic
epithelial cells [8-10]. The A986S polymorphism of the
CaSR gene has been suggested to increase the risk of other
proliferative disorders such as parathyroid adenoma [12].
In the present study, we aimed to investigate the potential
relationship between these polymorphisms and the inci-
dence and/or progression of CRC in the Hungarian popu-
lation.
Methods
Patients
In our study, we included 538 participants, 278 subjects
with primary CRC (130 female and 148 male) and 260
healthy blood donors between 2005 and 2007. Informa-
tion on clinical characteristics (age at the diagnosis, sex,
tumor location, TNM classification, stage groupings of the
American Joint Committee on Cancer (AJCC), disease
recurrence (locoregional and distant), disease-free sur-
vival (DFS), overall survival (OS), serum levels of carci-
noembryonic antigen (CEA), alpha1-fetoprotein (AFP),
carbohydrate antigen 19-9 (CA19-9), calcium and albu-
min were abstracted from medical records in oncology
centers. Age at the diagnosis was 61 ± 11 years. All CRCs
were histologically adenocarcinoma. Follow-up data were
obtained at every 6 months. The median follow-up period
was 17 months (range 1–20 months) in case of 215
patient (63 patient had no clinical follow-up data). The
median DFS was 10 months (range 1–20 months). DFS
was calculated for 154 patient (61 patient had metastasis
at the time of the diagnosis, thus, these patients were
excluded from DFS analysis). Twenty-nine participants
died during the observational period. Table 1 contains the
clinical and pathological data of the patients. The control
group consisted of 260 healthy Caucasian blood donors
without history of cancer or any chronic diseases. The
enrolment criteria in the control group included the lack
of gastrointestinal pain, family history for colorectal can-
cer and detection of blood in stool.
The A986S polymorphism of the CaSR gene and the
13910 C/T polymorphism of the LCT gene were investi-
gated both in the CRC and control groups. Samples were
handled anonymously in accordance with previously
established ethical protocols. The study was approved by
ethical committee. All subjects gave written informed con-
sent.
Genetic analysis of LCT 13910 C/T and CaSR A986S G/T 
polymorphisms
Genomic DNA was isolated from EDTA blood using a
commercially available kit (Magnesil KF Genomic System,
Promega, Madison, WI). LCT 13910 C/T (rs4988235) pol-
ymorphism involving a thymine (T) to cytosine (C) nucle-
otide change is located 13.9 kb upstream of lactase gene
(LCT) in intron 13 of the adjacent minichromosome
maintenance 6 (MCM6) [13]. It was genotyped with the
following sequence of allele specific probes 5'-ATA AGA
TAA TGT AGC CCC TGG C; 5'-ATA AGA TAA TGT AGT
CCC TGG C and primers (forward) 5'-CTC TGC GCTPage 2 of 8
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AGG AGG AGA. The PCR mixture (20 μL) contained 1 μL
genomic DNA (50 ng/μL), 0.18 μL primers (100 μmol/L;
Sigma-Genosys, Woodlans, Texas), 0.04 μL probes (100
μmol/L; Applied Biosystems, Foster City, CA), 10 μL of
TaqMan Universal PCR Assay Mix (Applied Biosystems)
and 8.56 μL ultrapure PCR water.
Genotyping for CaSR A986S G/T (rs1801725) was per-
formed by a Taqman Pre-Designed SNP Genotyping Assay
(Applied Biosystems) [14]. This genetic variance causes an
amino acid change from alanine (A) to serine (S) in the
protein sequence. The PCR mixture (20 μL) for CaSR
A986S polymorphism contained 1 μL genomic DNA (50
ng/μL), 0.50 μL 40× Taqman Pre-Designed SNP Genotyp-
ing Assay (Applied Biosystems), 10 μL of TaqMan Univer-
sal PCR Assay Mix (Applied Biosystems) and 8.50 μL
ultrapure PCR water.
Table 1: Clinical characteristics and tumor parameters of patients according to LCT 13910 C/T and CaSR A986S genotypes
LCT 13910 C/T genotypes CaSR A986S genotypes
TT + TC
(n = 125)
CC
(n = 90)
p value AA + AS
(n = 200)
SS
(n = 15)
p value
Age at the diagnosis (year) (mean ± SD) 60 ± 11 61 ± 10 0.54 61 ± 10 62 ± 13 0.64
Male/female (case number) 66/59 54/36 0.29 112/88 8/7 0.84
Tumor location (case number) 0.71a 0.40a
Rectum 69 52 111 10
Left colon 27 17 41 3
Right colon 29 21 48 2
TNM classification (case number)
T1 0 2 0.54b 2 0 0.22b
T2 25 13 37 1
T3 74 60 125 9
T4 26 15 36 5
N0 36 25 0.87c 54 7 0.10c
N1 58 43 96 5
N2 31 22 50 3
M0 88 66 0.49 143 11 0.88
M1 38 23 57 4
AJCC stages (case number) 0.87d 0.10d
I 10 6 15 1
IIA 13 10 20 3
IIB 13 9 19 3
IIIA 9 4 13 0
IIIB 26 20 44 2
IIIC 16 18 32 2
IV 38 23 57 4
Serum calcium (mmol/L), (mean ± SD) 2.39 ± 0.12 2.39 ± 0.11 0.85 2.39 ± 0.11 2.39 ± 0.16 0.91
Normal range (2.2–2.6)
Female 2.41 ± 0.11 2.36 ± 0.14 0.038e 2.39 ± 0.11 2.43 ± 0.18 0.42
Male 2.37 ± 0.12 2.39 ± 0.11 0.23 2.39 ± 0.11 2.35 ± 0.15 0.37
Adjusted serum calcium (mmol/L), (mean ± SD) 2.30 ± 0.11 2.30 ± 0.13 0.89 2.29 ± 0.11 2.35 ± 0.17 0.13
Normal range (2.09–2.54)
Female 2.31 ± 0.12 2.29 ± 0.11 0.31 2.29 ± 0.11 2.40 ± 0.19 0.036e
Male 2.29 ± 0.10 2.31 ± 0.14 0.54 2.29 ± 0.12 2.31 ± 0.14 0.89
Serum CEA (ng/mL), [median (interquartile range)] 3.33(25.16) 3.41(13.61) 0.79 3.34(16.13) 3.01(90.77) 0.89
Normal range (< 4.3)
Serum CA19-9 (U/mL), [median (interquartile range)] 11.15(92.09) 7.21(26.53) 0.59 9.77(42.66) 6.88(214.75) 0.98
Normal range (< 39)
Serum AFP (ng/mL), [median (interquartile range)] 3.81(2.23) 3.43(3.05) 0.58 3.57(2.33) 3.57(6.52) 0.94
Normal range (< 13.6)
aP value designates the association for rectum vs. other tumor site
bP value designates the association for T1+T2 vs. T3+T4 stages
cP value designates the association for N0 vs. N1+N2 stages
dP value designates the association for I-II vs. III-IV stages
eThe association did not remain significant after adjusting for multiple testing
Detailed data were available only for 215 CRC patientsPage 3 of 8
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both polymorphisms. Cycling conditions for genotypings
comprised an initial cycle at 60°C for 1 min and 95°C for
10 min, followed by 55 cycles at 92°C for 15 s and 60°C
for 1 min, and a final step at 60°C for 1 min. The fluores-
cence intensity of was measured by the 7500 RT-PCR Sys-
tem (Applied Biosystems).
Measurement of biochemical parameters (CEA, AFP, 
CA19-9, serum calcium and albumin)
Blood samples were obtained at the time of diagnosis of
CRC. Serum tumor markers, such as CEA, AFP and CA19-
9 were determined by electro-chemiluminescence immu-
noassays (Roche Diagnostics, Indianapolis, IN). Intra-
and inter-assay coefficients of variation (CV) for all previ-
ous assays were below 4.1%, 3.8% and 2.9%, for elevated,
normal and low serum concentrations, respectively.
Serum calcium and albumin were determined by colori-
metric assays (Roche Diagnostics). CVs were below 1.9%
and 1.7% for elevated and normal serum concentrations,
respectively. Calcium levels were corrected for serum
albumin: corrected serum calcium = serum calcium (mil-
limoles per liter)-0.02× [albumin (grams per liter) – 40)].
Statistical analysis
In the primary analysis, we separately investigated the
association between LCT 13910 C/T or CaSR A986S poly-
morphisms and disease recurrence and DFS. We exam-
ined locoregional and distant recurrences separately in the
analysis between disease recurrence and genotypes carried
out by binary logistic regression. Odds ratios (OR) and
95% confidence intervals (95% CI) were calculated. The
events were defined as distant disease recurrence for the
DFS analysis in Kaplan Meier method. The survival factor
levels were compared with Log rank test. In the secondary
analysis, we investigated the associations between these
polymorphisms and OS by Kaplan-Meier method with
Log rank test. The events were defined as death for the OS
analysis.
In basic statistics, we investigated the association between
the polymorphisms and cancer incidence by binary logis-
tic regression. The distributions of the variables were ana-
lyzed by Kolmogorov-Smirnov test. Means of continuous
variables with normal distribution (age at the time of
diagnosis, serum calcium, DFS and OS) were compared
among genotypes by analysis of variance. We used Mann-
Whitney unpaired t-test or Kruskal-Wallis tests to compare
the not normally distributed numerical variables (serum
albumin, serum CEA, serum CA19-9, serum AFP) among
genotypes. The associations between characteristics varia-
bles (gender, tumor location, TNM classification, AJCC
stages) and genotypes were investigated by Chi-square
test.
Analyzing the effect of LCT 13910 C/T polymorphism, we
evaluated CC genotypes vs. TT+TC genotypes based on
previous studies [6,15]. Additive, recessive and dominant
models were used to test the associations among CaSR
A986S genotypes and outcome parameters. The number
of risk allele (C allele for LCT 13910 C/T polymorphism
and S allele for CaSR A986S polymorphism) was used in
Spearman rank correlation to investigate the effect of
these two polymorphisms on variables. The Hochberg
procedure was used for multiple testing adjustment, and
adjusted p < 0.05 was used as the significant criterion. The
results were given as mean ± standard deviation (SD) for
parameters with normal distribution or median (inter-
quartile range) for variables without normal distribution.
The data were analyzed using the SPSS statistical package
(SPSS Inc., Chicago, IL; version 15.0 for Windows).
Results
Genotype frequencies followed the Hardy-Weinberg equi-
librium. The distant disease recurrence (during the
median 17 months follow-up period) was different in LCT
genotypes: a significantly higher CC frequency was seen in
patients distant disease recurrence (OR = 4.04; 95% CI =
1.71–9.58; p = 0.006) (Table 2). Also, the DFS, calculated
from distant recurrence, was altered according to geno-
types with reduced DFS for patient with LCT CC geno-
types (log rank test p = 0.008) (Table 2 and Fig. 1). Age of
patients was not different in the genotype groups (61 ± 10
years for CC genotype and 60 ± 11 years for TT + TC gen-
otypes, p = 0.54). The locoregional disease recurrence and
OS were not associated with LCT 13910 C/T genotypes
(Table 2).
Table 2: The disease recurrences and DFS, OS according to genotypes in the patient group
LCT 13910 C/Ta CaSR A986Sa
OR 95% CI p value OR 95% CI p value
Distant recurrence 4.04 1.71–9.58 0.006 1.07 0.23–4.33 0.93
Locoregional recurrence 1.37 0.49–3.87 0.55 0.63 0.08–5.19 0.66
DFS - - 0.008b - - 0.81b
OS - - 0.44b - - 0.49b
aThe parameter for CC vs. TT+TC genotypes or SS vs. AA+AS genotypes were compared
blog rank test p valuePage 4 of 8
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level between female patients with CC genotype and with
TT/TC genotypes, however it did not remain significant
after correction for multiple testing. None of the other
investigated laboratory and clinical variables showed any
correlations with this LCT polymorphism (Table 1). Can-
cer incidence was not influenced by this genetic variation
(OR = 1.20; 95% CI = 0.85–1.69; p = 0.30).
CaSR A986S polymorphism did not show any associa-
tions with tumor recurrence (distant and locoregional),
DFS or OS in recessive (Table 2) or in additive and domi-
nant models (data were not shown). Examining this pol-
ymorphism further, cancer incidence was found to be
increased in the recessive model (OR = 4.01; 95% CI =
1.33–12.07; p = 0.042): the homozygous CaSR SS geno-
type was more frequent in patients than controls. This
relationship was not significant when examined in domi-
Kaplan-Meyer estimates of LCT 13910 genotypes for DFS in CRC patientsFigure 1
Kaplan-Meyer estimates of LCT 13910 genotypes for DFS in CRC patients. Patients with LCT 13910 CC genotype had worse 
outcome compared to TC + TT genotypes (log rank test p = 0.008).
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quency of the S allele was significantly higher in CRC
patients than in controls (Table 3).
Serum calcium concentrations were elevated in female
subjects with SS genotype compared to AA/AS genotypes
(Table 1), however, this correlation did not remain signif-
icant after correction for multiple testing. Other examined
laboratory and clinical variables were not different among
CaSR genotypes (Table 1). Serum calcium levels did not
correlate with the survival parameters (DFS, OS, locore-
gional and distant recurrences in the follow-up period) or
other laboratory values.
The number of LCT C and CaSR S risk alleles were associ-
ated with increasing tumor incidence (p = 0.035). In addi-
tion, the CCSS genotype combination (n = 5) was found
only in patients with CRC (p = 0.033). Similar association
was not observed with survival parameters (DFS, OS,
locoregional and distant recurrences in follow-up period)
or laboratory values.
Discussion
In our study, we have found a significant correlation
between LCT 13910 C/T polymorphism and the progres-
sion of CRC. Rasinpera et al. [6] found that the CC geno-
type was more frequent in the patient group in the Finnish
population. We could not detect this association, how-
ever, CC genotype frequency was higher in the Hungarian
population in general (patients: 41%, controls: 36%) than
that for the Finnish population (patients: 23.5%, controls:
18%). On the other hand, we could show a decreased sur-
vival rate in CRC patients with CC genotype. This aspect
was not examined in the Finnish study since it had a cross-
sectional design. The reduced survival of subjects with CC
genotype could not be attributed to the more advanced
age of these patients since there was no difference in this
respect between genotype groups.
Some authors have demonstrated that the CC genotype is
associated with low LPH-specific mRNA expression and
LPH activity in intestinal biopsy samples [16,17]. Also,
close relationship was observed between the positive
result of hydrogen breathing test and CC genotype [18].
Patients with LI consume less milk products, which is the
main source of calcium [3,4]. Non-digested lactose in LI
can additionally impair calcium absorption further aggra-
vating negative calcium balance [19]. The reduction in cal-
cium absorption can also be seen in subjects with positive
breathing test but without clinical symptoms (11–32% of
all lactose intolerant patients) [3,4]. In our study, subjects
with CC genotype had lower serum calcium, although this
correlation disappeared after correcting for multiple test-
ing.
Increased calcium intake may reduce CRC incidence sug-
gesting that calcium could be an important chemopreven-
tive factor in colorectal carcinogenesis [2,10,20,21].
Reduced calcium intake will result in reduced intralumi-
nal calcium concentration, and as a consequence,
increased amounts of free bile and fatty acids. Calcium
binds to bile and fatty acids, forming insoluble com-
plexes, thus, reducing their free concentrations in the
intestinal tract [22-24]. Free bile and fatty acids may pro-
mote carcinogenesis [24]. In addition, calcium itself may
inhibit hyperproliferation of colonic epithelial cells
[2,21,25].
Digestion of lactose by LPH will produce galactose that
may also add to the pathogenetic process leading to the
development of CRC, producing lower amount of galac-
tose as enzyme product. One of the most common glyco-
lysation abnormalities in colon cancer is the increased
mucosal expression of the galactose-β-1,3-N-acetilgalac-
tosamine, known as the Thomsen-Friedenreich blood
group antigen [26]. This compound is able to bind to
lectins, known factors of stimulated colon epithelial pro-
liferation. Intestinal galactose produced by LPH enzyme
has a protective effect against CRC by binding lectins,
thus, inhibiting mucosal proliferation [27]. In LI, i.e. in
the presence of CC genotype, the amount of intestinal
galactose is decreased due to the insufficient LPH concen-
tration. This mechanism may also contribute to the nega-
Table 3: Genotype distributions regarding study groups
LCT 13910 C/T CaSR A986S
Patients n = 278 Controls n = 260 p value Patients n = 278 Controls n = 260 p value
Genotype distribution (n (%))
TT or AA 46 (16) 48 (19) 186 (67) 188 (72)
TC or AS 119 (43) 117 (45) 75 (27) 68 (26)
CC or SS 113 (41) 95 (36) 17 (6) 4 (2)
C or S allele frequency 0.62 0.59 0.60 0.20 0.15 0.025
OR (95% CI)a 1.20 (0.85–1.69) 0.30 4.01 (1.33–12.07) 0.042
OR (95% CI) in interaction analysis (C and S alleles) 1.25 (1.03–1.52) p = 0.026
aThe parameter for CC vs. TT+TC genotypes or SS vs. AA+AS genotypes were comparedPage 6 of 8
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in our study.
The CaSR A986S polymorphism appeared to have an
impact on CRC incidence in our study. CaSR serves as a
messenger system in controlling calcium homeostasis.
CaSR is a G protein-coupled receptor [28] and it is respon-
sible for modulating PTH and calcitonin release in
response to alterations in extracellular calcium levels.
Also, extracellular calcium concentration inhibits 1,25-
dihidroxyvitamin D3 synthesis in renal proximal cells
mediated by CaSR [29,30]. Higher concentration of cal-
cium inhibits the proliferation of cancer cells [8-10]. In
colonic epithelial cell lines, extracellular calcium regulates
the differentiation and proliferation via the CaSR [8-10].
CaSR has been reported most highly expressed in well-dif-
ferentiated regions of colon cancer and nearly lacking in
poorly differentiated sites [8]. CaSR A986S polymor-
phism causing impaired sensing of extracellular calcium
might contribute to the development of colorectal cancer.
In this case, elevated extracellular calcium could not act as
preventive factor on the altered CaSR. This hypothesis is
strengthened by our findings that CaSR SS genotype with
reduced calcium-sensing capacity was more frequent in
CRC patients.
The stimulation of the CaSR may decrease colorectal car-
cinogenesis through several mechanisms. It promoted E-
cadherin expression, a transmembran glycoprotein that
functions in cell-cell adhesion and epithelial integrity [8].
Calcium/CaSR also suppress β-catenin – T cell factor
(TCF) activation, which is responsible for the expression
of broad range of malignant effectors, such as c-myc, gas-
trin, cyclin D1, cyclo-oxigenase-2 (COX-2), matrilysin,
urokinase-type plasminogen activator, CD44, multidrug
resistence-1 gene and its product P-glycoprotein [8,31].
On the other hand, the activation of CaSR results in cell
growth and differentiation control by the mitogen-acti-
vated protein kinase (MAPK) system [10]. This stimula-
tion is elicited through filamin-A that is bound to the
intracellular region of CaSR containing the A986S muta-
tion site [32,33]. In the mutated CaSR, stimulation of
MAPK is impaired, thus, cells may proliferate in an uncon-
trolled manner. As a proof of this putative mechanism, SS
genotype was accompanied with increased risk of CRC in
our study.
According to our results, both LCT and CaSR gene poly-
morphisms appear to affect CRC incidence/progression.
The negative effects of LCT C and CaSR S alleles could be
additive since the number of copies of these disadvanta-
geous genetic variations was accompanied with increasing
incidence of CRC. In addition, CCSS genotype combina-
tion was only found in patients with CRC.
The limitations of our study include the relatively short
follow-up period of 17 months, as well as the lack of
detailed evaluation of calcium consumption. We did not
explore underlying mechanisms either that could explain
the observed correlations between the LCT/CaSR poly-
morphisms and the examined factors.
Conclusion
Our results suggest that the LCT 13910 CC genotype may
affect tumor recurrence and disease-free survival, while
the modified calcium signaling in the CaSR 986 SS geno-
type could lead to increased incidence of CRC. The impor-
tance of these findings requires further investigations.
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